Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around

Description

Summary

This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.

Official Title

A Phase II Study of sEphB4-HSA in Kaposi Sarcoma

Details

Keywords

Skin Kaposi Sarcoma, Kaposi Sarcoma, Sarcoma, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Recombinant EphB4-HSA Fusion Protein

Eligibility

Locations

  • UCLA CARE Center
    Los Angeles California 90025 United States
  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • UCSD Moores Cancer Center
    La Jolla California 92093 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AIDS Malignancy Consortium
ID
NCT02799485
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 23 people participating
Last Updated